Search alternatives:
point decrease » point increase (Expand Search)
ppm decrease » _ decrease (Expand Search), pa decreased (Expand Search), 026 decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 point » _ point (Expand Search)
point decrease » point increase (Expand Search)
ppm decrease » _ decrease (Expand Search), pa decreased (Expand Search), 026 decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 point » _ point (Expand Search)
-
15181
Table_3_CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease.xlsx
Published 2023“…According to KEGG pathways enrichment analysis, the methylated genes CACNA1B (hypomethylated), CREB5 (hypermethylated), GNB4 (hypomethylated), and PPP2R5A (hypomethylated) were enriched in the dopaminergic synapse pathway. …”
-
15182
Table_3_CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease.xlsx
Published 2023“…According to KEGG pathways enrichment analysis, the methylated genes CACNA1B (hypomethylated), CREB5 (hypermethylated), GNB4 (hypomethylated), and PPP2R5A (hypomethylated) were enriched in the dopaminergic synapse pathway. …”
-
15183
Table_1_CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease.doc
Published 2023“…According to KEGG pathways enrichment analysis, the methylated genes CACNA1B (hypomethylated), CREB5 (hypermethylated), GNB4 (hypomethylated), and PPP2R5A (hypomethylated) were enriched in the dopaminergic synapse pathway. …”
-
15184
Table_2_CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease.docx
Published 2023“…According to KEGG pathways enrichment analysis, the methylated genes CACNA1B (hypomethylated), CREB5 (hypermethylated), GNB4 (hypomethylated), and PPP2R5A (hypomethylated) were enriched in the dopaminergic synapse pathway. …”
-
15185
Table_1_CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease.doc
Published 2023“…According to KEGG pathways enrichment analysis, the methylated genes CACNA1B (hypomethylated), CREB5 (hypermethylated), GNB4 (hypomethylated), and PPP2R5A (hypomethylated) were enriched in the dopaminergic synapse pathway. …”
-
15186
-
15187
-
15188
-
15189
-
15190
Table_1_An Immune Gene-Related Five-lncRNA Signature for to Predict Glioma Prognosis.DOCX
Published 2020“…Coexpressed lncRNAs were analyzed to generate a model of lncRNAs and immune-related genes. We analyzed the model using survival and Cox regression. …”
-
15191
-
15192
-
15193
DataSheet3_LAMP5 may promote MM progression by activating p38.ZIP
Published 2023“…Western blotting assay also found more expression of LAMP5 in NDMM than in HD. Patients with high LAMP5 expression have a higher DS (Durie-Salmon) stage and worse prognosis. …”
-
15194
-
15195
Data Sheet 1_Diethyl butylmalonate attenuates cognitive deficits and depression in 5×FAD mice.docx
Published 2024“…In addition, DBM decreased the accumulation of microglia and downregulated neuroinflammation in the hippocampus and amygdala of 5×FAD mice.…”
-
15196
-
15197
DataSheet1_LAMP5 may promote MM progression by activating p38.ZIP
Published 2023“…Western blotting assay also found more expression of LAMP5 in NDMM than in HD. Patients with high LAMP5 expression have a higher DS (Durie-Salmon) stage and worse prognosis. …”
-
15198
DataSheet4_LAMP5 may promote MM progression by activating p38.ZIP
Published 2023“…Western blotting assay also found more expression of LAMP5 in NDMM than in HD. Patients with high LAMP5 expression have a higher DS (Durie-Salmon) stage and worse prognosis. …”
-
15199
-
15200
Comparison of 10 emerging SARS-CoV-2 Variants: infectivity, animal tropism, and antibody neutralization
Published 2021“…However, the resistance to neutralization by convalescent serum or vaccines was mainly caused by the E484K mutation, while the neutralization of E484K-carrying variants was decreased by 1.1–6.2-fold. <a>The convalescent serum from B.1.1.7- and B.1.351-infected patients neutralized the variants themselves better than other SARS-CoV-2 variants.…”